{'fraction_non_alphanumeric': 0.04576043068640646, 'fraction_numerical': 0.010767160161507403, 'mean_word_length': 5.2521008403361344, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Therapy and clinical trials: beyond low-density lipoprotein cholesterol reduction.

Low-density lipoprotein cholesterol vs. high-density lipoprotein cholesterol as target Coronary heart disease (CHD) morbidity and mortality are widely accepted as being associated with decreases in plasma low-density lipoprotein cholesterol (LDL-C) and current guidelines recommend statins as first-line drug therapy given the abundance of clinical endpoint data, both in primary and secondary prevention. [1]. Though CHD risk is reduced by 22–35% in statin trials [2 ], a vast majority still experience CHD events despite aggressive lowering of LDL-C levels [3], and low high-density lipoprotein cholesterol (HDL-C) is a major risk factor in this group [2 ].